Chemistry:SSR-180,711
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H21BrN2O2 |
| Molar mass | 329.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
SSR180711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.[3][4]
References
- ↑ "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology 32 (1): 17–34. January 2007. doi:10.1038/sj.npp.1301188. PMID 16936709.
- ↑ "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology 32 (1): 1–16. January 2007. doi:10.1038/sj.npp.1301189. PMID 17019409.
- ↑ "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry 63 (1): 92–7. January 2008. doi:10.1016/j.biopsych.2007.04.034. PMID 17601496.
- ↑ "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia". Neuropsychopharmacology 34 (7): 1753–63. June 2009. doi:10.1038/npp.2008.232. PMID 19158670. http://ggriebel.perso.worldonline.fr/Pub107.pdf.
 |  |
